Elite Pharmaceuticals INC /NV/ 8-K filings

Elite Pharmaceuticals, Inc. announced it will host a conference call on August 14, 2026, to discuss its first quarter fiscal year 2027 financial results, which will be released on August 13, 2026.

Elite Pharmaceuticals announces the commercial launch of its generic version of Requip XL (Ropinirole Extended-Release Tablets USP) in multiple strengths.

Elite Pharmaceuticals announced a significant increase in consolidated revenues and income from operations for the fiscal year ended March 31, 2026, driven by new product launches and existing product growth.

Elite Pharmaceuticals announced positive results from a pivotal bioequivalence study for a generic anticonvulsant drug, moving closer to an FDA Abbreviated New Drug Application.

Elite Pharmaceuticals announced the submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic anticoagulant product.

Elite Pharmaceuticals, Inc. announced it will host a conference call on February 18, 2026, to discuss its third-quarter fiscal year 2026 financial results.

Elite Pharmaceuticals, Inc. reported a significant 92% increase in consolidated revenues to $36.3 million for the second quarter of fiscal year 2026, driven by strong sales of lisdexamfetamine products.

Elite Pharmaceuticals, Inc. announced it will release its second quarter fiscal year 2026 financial results on November 14, 2025, and host a conference call on November 17, 2025, to discuss them, with an 8-K/A correcting the call date.

Elite Pharmaceuticals, Inc. announced FDA approval for its generic version of Requip XL (Ropinirole Extended-Release Tablets USP) for Parkinson's disease.

Elite Pharmaceuticals, Inc. announced it will host a conference call on November 17, 2025, to discuss its second quarter fiscal year 2026 financial results.

Elite Pharmaceuticals, Inc. announced a significant increase in first-quarter fiscal year 2026 revenues and operating profits, driven by new product launches and strong label product growth.

Elite Pharmaceuticals, Inc. announced a conference call to discuss its first quarter fiscal year 2026 financial results on August 15, 2025.

Elite Pharmaceuticals, Inc. announced substantial increases in consolidated revenues and operating profits for the fiscal year ended March 31, 2025, primarily fueled by the successful launch of lisdexamfetamine products and strong performance from existing product lines.

Elite Pharmaceuticals, Inc. announced it will release its fiscal year 2025 financial results on June 30, 2025, and host a conference call on July 1, 2025, to discuss the results and provide a corporate update.

Elite Pharmaceuticals, Inc. announced positive results from a pivotal bioequivalence study for an undisclosed generic anticoagulant drug product, a significant step towards entering a market with $27 billion in annual branded sales.

Elite Pharmaceuticals announces the commercial launch of its generic version of Percocet (oxycodone hydrochloride and acetaminophen tablets).

Elite Pharmaceuticals has announced the shipment of its first finished product from its newly expanded and FDA-approved facility in Northvale, NJ.

Elite Pharmaceuticals announced its Q3 fiscal year 2025 results, reporting a decrease in revenue and operating profits, and will host a conference call to discuss the results and provide a business update.

Elite Pharmaceuticals has announced the commercial launch of its generic version of Vyvanse, a medication used to treat ADHD.

Elite Pharmaceuticals has announced the commercial launch of its generic version of Norco tablets, a pain management medication.

Elite Pharmaceuticals has secured FDA approval for its generic version of Vyvanse, a drug used to treat ADHD.

Elite Pharmaceuticals announced a 33% increase in revenue and an 84% increase in operating profits for the second quarter of fiscal year 2025, ended September 30, 2024.

Elite Pharmaceuticals has secured approval from the Israeli Ministry of Health for its generic version of Adderall, to be distributed by Dexcel Pharma.

Elite Pharmaceuticals has announced the commercial launch of its generic version of Tylenol with Codeine tablets.

Elite Pharmaceuticals has announced the commercial launch of its generic methotrexate sodium 2.5 mg tablets.

Elite Pharmaceuticals announced a significant 109% increase in revenue and a 144% increase in operating profits for the first quarter of fiscal year 2025.

Elite Pharmaceuticals announced a substantial increase in revenue and operating profit for fiscal year 2024, driven by the launch of its Elite label product line.

Elite Pharmaceuticals has acquired the rights to three generic pain medication ANDAs from Nostrum Laboratories for $900,000 in cash.

Elite Pharmaceuticals Inc. has changed its independent registered public accounting firm from Mazars USA LLP to Forvis Mazars, LLP, effective June 1, 2024, due to a merger.

Elite Pharmaceuticals has received FDA approval for its generic version of Methotrexate Sodium 2.5 mg tablets, a drug used to treat certain cancers and autoimmune diseases.